Compliance

DVT Prophylaxis Patient Education: Discharge Documentation Across Surgical Specialties

Venous thromboembolism (VTE) is a preventable complication across a wide range of surgical specialties. Discharge documentation for DVT prophylaxis patient education must address the specific prophylaxis agent ordered, duration requirements, administration instructions, and the warning signs that require emergency evaluation. This guide covers the documentation requirements, prophylaxis-specific patient education content, VTE quality measure reporting, and the elements that reduce post-operative VTE-related emergency contacts.

VTE Risk and Prophylaxis Documentation Requirements by Specialty

VTE risk after surgery varies substantially by procedure type and patient risk factors. The American College of Chest Physicians (ACCP) publishes antithrombotic therapy guidelines that stratify surgical patients by VTE risk level (low, moderate, high) based on procedure type, duration of surgery, patient age, prior VTE history, cancer diagnosis, and other risk factors. Discharge documentation for DVT prophylaxis should identify the risk stratification applied and the prophylaxis selection that corresponds to the patient's risk category, enabling subsequent providers to verify that appropriate prophylaxis was prescribed.
For major orthopedic surgery including total hip arthroplasty, total knee arthroplasty, and hip fracture repair, the ACCP guidelines recommend extended-duration pharmacologic prophylaxis of 10 to 35 days depending on the procedure. Discharge instructions for patients in this category must specify the total duration of prophylaxis, not just the in-hospital portion. Patients who are discharged on a 10-day aspirin prescription after TKA and told only to take aspirin daily without a specified endpoint do not have adequate instructions to comply with the intended prophylaxis course.
Abdominal and pelvic surgery patients, particularly those with cancer, are at elevated VTE risk per ACCP risk stratification criteria. Extended-duration pharmacologic prophylaxis of 28 days is recommended for high-risk abdominal or pelvic cancer surgery patients per the ACCP guidelines. Discharge documentation for these patients must specify the 28-day endpoint, the medication name and dose, and the administration schedule to support the full prophylaxis duration.
The CMS Hospital Inpatient Quality Reporting program includes VTE quality measures for hospital settings, including VTE-6, which requires documentation that the patient received VTE education covering the risk of VTE and the recommended prophylaxis before discharge. Patients discharged from a hospital-based surgical setting must have a record of this education to meet the VTE-6 numerator criteria. Outpatient and ASC settings are not directly subject to hospital VTE quality measures, but the same educational documentation practices apply as a standard of care.
Patients discharged with a retrievable inferior vena cava (IVC) filter in place require discharge documentation that addresses: the filter placement, whether it is retrievable or permanent, the plan and timeline for retrieval follow-up, and the specific indications for anticoagulation initiation in the post-operative period. Patients with IVC filters still require education on VTE warning signs and on the symptoms that indicate filter complications, including back pain, abdominal pain, and new leg swelling.

Agent-Specific Patient Education Content

Aspirin for VTE prophylaxis is used predominantly in elective orthopedic surgery for lower-risk THA and TKA patients. Discharge instructions for aspirin prophylaxis must specify: the dose (81 mg or 325 mg, which varies by surgeon protocol), the frequency (once or twice daily), the duration in days, whether food is recommended to reduce GI irritation, and the circumstances under which aspirin should be held. Patients should be instructed not to substitute other NSAIDs for aspirin without provider guidance, as NSAID substitution does not provide equivalent VTE prophylaxis.
Low-molecular-weight heparin (LMWH, enoxaparin) instructions must include: the brand name and generic name, the specific dose in milligrams, the frequency (once or twice daily), the total number of days of administration, subcutaneous injection technique with site rotation guidance, and disposal instructions for sharps. Patients who have not previously self-administered injections require a return demonstration of injection technique before discharge. Documentation of the return demonstration and the patient's demonstrated competency is part of the discharge record.
Direct oral anticoagulants prescribed for VTE prophylaxis after surgery (rivaroxaban, apixaban) require food-specific administration instructions. Rivaroxaban for post-surgical VTE prophylaxis should be taken with the evening meal per the prescribing information to optimize absorption. Apixaban does not require food. Discharge instructions must specify the exact timing relative to meals, since incorrect administration reduces bioavailability and compromises prophylaxis effectiveness. Instructions must also address drug-drug interactions with strong CYP3A4 inhibitors and the follow-up plan for duration management.
Warfarin discharge instructions require additional elements not needed for fixed-dose agents: the starting dose, the INR target range, the schedule and location for INR monitoring, the foods high in vitamin K that can affect INR stability, the drug interactions most clinically relevant for surgical patients (antibiotics, antifungals, NSAIDs), and the protocol for missed doses. Patients transitioning from LMWH bridging to warfarin need to understand the overlap period and when it is safe to stop the LMWH injection.
Fondaparinux is used in some surgical patients, particularly those with heparin-induced thrombocytopenia (HIT) risk. Discharge instructions for fondaparinux must address: subcutaneous injection technique, the renal dosing restriction (fondaparinux is contraindicated in patients with creatinine clearance below 30 mL/min), and the duration. Patients who are at HIT risk should be told why a different agent from heparin or LMWH was selected, since they may encounter heparin or LMWH at other facilities during the recovery period.

VTE Warning Sign Communication Requirements

Discharge instructions for all surgical patients on VTE prophylaxis must include explicit written description of DVT and pulmonary embolism warning signs. DVT symptoms that require evaluation include: pain, tenderness, or cramping in the calf, thigh, or groin on the operated or unoperated extremity; new or worsening swelling of the leg; redness, warmth, or skin discoloration along the course of a vein. Instructions should distinguish expected post-operative swelling (bilateral, diffuse, present at the ankle and foot) from DVT-pattern swelling (unilateral, progressive, appearing days after surgery in a previously improved leg).
Pulmonary embolism symptoms must be clearly identified as requiring 911 activation rather than a call to the practice. Symptoms that indicate possible PE include: sudden shortness of breath, chest pain that is worse with breathing, rapid or irregular heartbeat, coughing up blood, lightheadedness or loss of consciousness, and leg pain accompanied by any respiratory symptom. Instructions that list PE symptoms as conditions to call the office about create a dangerous delay. The 911 instruction must be explicit in the written discharge materials.
Instructions should also address upper-extremity DVT for patients who had central venous catheters, port placement, or arm-based IV access. Upper extremity DVT symptoms include arm pain, swelling, redness, or warmth at the catheter insertion site or along the arm. Central venous catheter-associated DVT is a recognized complication in patients who have undergone thoracic, neck, or upper extremity procedures and those who received intraoperative central access.
The written instructions should explicitly state when prophylaxis medication should not be held. Patients sometimes stop anticoagulation if they experience minor bleeding such as nosebleed, gum bleeding, or bruising, and do not resume it. Instructions should specify that minor bleeding does not require stopping the prophylaxis medication, and that major bleeding (significant bleeding that does not stop with pressure, blood in stool or urine, vomiting blood) requires immediate medical evaluation and a call to the prescribing provider before making any changes to the prophylaxis regimen.

Documentation Standards for VTE Prophylaxis Patient Education

The medical record should contain a documentation element that confirms the patient received VTE prophylaxis education and the content that was covered. A checklist embedded in the discharge note or a standalone discharge education form should record: the prophylaxis agent discussed, the duration explained, DVT and PE warning signs reviewed, return precautions given, and the patient's or caregiver's demonstrated understanding of the instructions. A generic notation of discharge instructions given without identifying VTE prophylaxis content does not satisfy the VTE-6 measure or the standard of care documentation requirement for anticoagulation education.
Patients with limited English proficiency must receive VTE prophylaxis instructions in a language they understand. Federal requirements under the Civil Rights Act and CMS Conditions of Participation require that covered entities provide meaningful access to communication for patients with LEP. Written discharge instructions that include DVT and PE warning signs must be translated into the patient's primary language or provided with a qualified interpreter. Providing English-only instructions to an LEP patient for anticoagulation management creates both a clinical safety risk and a civil rights compliance issue.
Patient understanding should be assessed using the teach-back method for VTE prophylaxis instructions. This means asking the patient to explain back, in their own words, how they will take the prophylaxis medication and what symptoms would lead them to call 911. The fact that teach-back was performed and the patient's ability to demonstrate understanding should be documented in the record. For patients who require repeated explanation, the record should note the number of explanation cycles and the specific points that required reinforcement.
Post-discharge VTE events should be tracked as a quality indicator. Practices that track VTE events (DVT or PE diagnosed within 30, 60, or 90 days of a qualifying surgical procedure) can identify whether specific prophylaxis agents, durations, or instruction gaps are associated with higher event rates. The CMS QCDR and MIPS quality measure frameworks include VTE-related measures for reporting purposes, and internal tracking supports the practice's quality improvement program independent of external reporting requirements.

Readmission Reduction for Orthopedic Surgery: Evidence-Based Protocols Reducing Unplanned Returns After Total Hip Replacement: Discharge Documentation Strategies Reducing Unplanned Returns After Total Knee Replacement: Discharge Documentation Strategies Post-Operative Pain Management Documentation: Regulatory Requirements and Compliance Standards Perioperative Antibiotic Prophylaxis: SCIP Measures and Stewardship Compliance

Frequently asked

Questions patients ask.

How long must DVT prophylaxis be continued after outpatient surgery?

The recommended duration of DVT prophylaxis after outpatient surgery depends on the procedure type, patient risk factors, and applicable clinical guidelines. The ACCP antithrombotic therapy guidelines recommend 10 to 35 days of prophylaxis after total hip or knee arthroplasty, with extended duration of 28 days for high-risk abdominal or pelvic cancer surgery. For low-risk outpatient procedures, mechanical prophylaxis during the perioperative period may be sufficient. Discharge instructions must state the specific duration in days, since take the medication as directed without a specified endpoint leads to early discontinuation and incomplete prophylaxis coverage.

What are the documentation requirements for VTE patient education under the VTE-6 quality measure?

CMS Hospital VTE Measure 6 (VTE-6) requires that patients discharged from inpatient hospital settings on anticoagulation for VTE treatment or prophylaxis receive written discharge instructions covering: the importance of follow-up monitoring, compliance with medication, dietary restrictions where applicable, and information about what to do if signs of bleeding or VTE recurrence occur. Documentation must reflect that each of these elements was addressed in the patient education provided before discharge. For outpatient and ASC settings, VTE-6 does not apply directly, but the same content requirements represent the standard of care for anticoagulation education at discharge.

When should a patient receiving post-surgical LMWH call 911 versus calling the practice?

Patients on LMWH should be instructed to call 911 for: sudden shortness of breath or difficulty breathing; chest pain that is worse with breathing; rapid or irregular heartbeat; coughing up blood; or leg pain accompanied by any respiratory symptom. These symptoms indicate possible pulmonary embolism, which is a time-sensitive emergency where delay in treatment increases mortality risk. Patients should call the practice for: minor bleeding (nosebleed, bruising, gum bleeding); questions about injection technique or missed doses; local injection site reactions; and suspected DVT symptoms (calf or thigh pain, leg swelling) not accompanied by respiratory symptoms. The distinction between 911 and practice contact symptoms should be explicit in the written discharge instructions.

What documentation is required when a patient receives LMWH injection training at discharge?

For patients who will self-administer LMWH after discharge, the education record should document: the date and time of the injection training session, the clinician who provided the training, the specific injection technique steps covered (site selection, skin preparation, pinching technique, needle angle, plunger activation, disposal), the patient's return demonstration of the injection technique, the patient's demonstrated ability to perform the injection safely, any areas requiring additional instruction, and the patient's ability to correctly identify signs of injection site complications. The return demonstration documentation is the key element: it establishes that instruction was confirmed through observed patient performance, not merely provided didactically.

For practices

Bring this to your own practice.

QR Rx turns every procedure into a branded recovery plan that keeps patients engaged and brings them back. Start free in minutes, or see it live in a 20-minute demo.

Start free trial

This blog provides general information about healthcare compliance and aftercare best practices. It does not constitute legal, medical, or regulatory advice. Consult qualified professionals for guidance specific to your practice.